Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director Daniel Swisher, Jr. sold 1,500 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $74.07, for a total transaction of $111,105.00. Following the completion of the sale, the director directly owned 1,100 shares of the company’s stock, valued at approximately $81,477. The trade was a 57.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Corcept Therapeutics Trading Down 1.0%
NASDAQ:CORT traded down $0.77 during trading hours on Friday, reaching $72.94. 1,112,926 shares of the company were exchanged, compared to its average volume of 1,293,167. The stock’s 50-day moving average is $103.70 and its 200-day moving average is $76.43. The firm has a market cap of $7.98 billion, a PE ratio of 57.43 and a beta of 0.54. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.17. The business had revenue of $340.47 million for the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The company’s revenue was up 64.0% compared to the same quarter last year. During the same period last year, the firm posted $0.16 earnings per share. As a group, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.97 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on CORT shares. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a report on Monday, July 27th. Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Piper Sandler restated an “overweight” rating and issued a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday, November 4th. Zacks Research lowered Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Finally, Wall Street Zen raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $139.50.
View Our Latest Stock Analysis on CORT
Institutional Investors Weigh In On Corcept Therapeutics
A number of hedge funds have recently modified their holdings of the business. Jump Financial LLC purchased a new position in shares of Corcept Therapeutics in the third quarter worth about $973,000. FORA Capital LLC purchased a new stake in Corcept Therapeutics during the 3rd quarter valued at about $1,166,000. EP Wealth Advisors LLC grew its stake in Corcept Therapeutics by 5.9% during the 3rd quarter. EP Wealth Advisors LLC now owns 5,136 shares of the biotechnology company’s stock valued at $592,000 after acquiring an additional 286 shares in the last quarter. Pathstone Holdings LLC grew its stake in Corcept Therapeutics by 1.6% during the 3rd quarter. Pathstone Holdings LLC now owns 11,535 shares of the biotechnology company’s stock valued at $1,329,000 after acquiring an additional 180 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in Corcept Therapeutics by 118.1% in the 3rd quarter. Marshall Wace LLP now owns 12,273 shares of the biotechnology company’s stock valued at $1,414,000 after acquiring an additional 6,645 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Recommended Stories
- Five stocks we like better than Corcept Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
